bluebird bio, Inc.: debt financing — bluebird bio enters $100M accounts receivable factoring agreement to accelerate cash collection

bluebird bio, Inc.

Up to $100M revolving factoring facility, 90% advance rate on receivables for LYFGENIA, ZYNTEGLO, SKYSONA.
Fee: prime rate + 1.35% on funded amount plus 0.05% collateral monitoring fee; proceeds for working capital.
12-month initial term, renewable annually; early termination fee 2% (first year) or 0.75% thereafter.
Purchaser assumes credit risk; seller must repurchase ineligible or disputed accounts.
Bylaws amended to adopt universal proxy rules and enhance disclosure for stockholder nominations.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

bluebird bio, Inc. incurred debt of up to $100,000,000.00 with Alterna Capital Solutions LLC at prime rate plus 1.35% maturing 12 months.

Principal: up to $100,000,000.00
Counterparty: Alterna Capital Solutions LLC
Rate: prime rate plus 1.35%
Maturity: 12 months
Event: incurrence

Exact text from the filing

The factoring facility provides for the Company to have access to up to $100,000,000.00 (the “Maximum Credit”) on a revolving basis

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

bluebird bio, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require proxy card color other than white, delete obsolete provisions, and make technical changes (effective 2023-12-14).

Change: bylaw amendment
Effective: 2023-12-14

Exact text from the filing

On December 14, 2023, the Board of Directors (the “Board”) of the Company approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

bluebird bio, Inc. entered into Agreement with Alterna Capital Solutions LLC valued at $100,000,000.00 (effective 2023-12-14).

Action: entry
Agreement: credit facility
Counterparty: Alterna Capital Solutions LLC
Value: $100,000,000.00
Effective: 2023-12-14

Exact text from the filing

On December 14, 2023, bluebird bio, Inc. (the “Company”) entered into an accounts receivable factoring agreement (the “Agreement”) with Alterna Capital Solutions LLC (the “Buyer”).

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001193125-23-297683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.